On Monday, May 24th, Investors are anticipating that Phase 3 will have great results. NOVN is currently trading +7% higher than Friday’s close.
“We are incredibly pleased with the progress we have continued to make as we advance our lead program. We remain focused on executing our remaining steps according to plan and reporting topline efficacy and safety data in June. On behalf of Novan, I would like to extend our sincere gratitude to the patients, families and clinical staff that have participated in the study.”
Paula Brown Stafford — President and CEO of Novan
Paula, the CEO of Novan stated in this early report that Novan focusing on executing their remaining steps and plan to report their topline efficacy and safety data in June of next month.
Today and the weeks leading up to June, investors are rallying up shares on the potential that the Phase 3 results have.
Many investors believe that Novan’s treatment is a breakthrough to treating Molluscum in the event that Phase 3 trial results are upstanding.
Upcoming Catalysts
- Topline efficacy results for ongoing Phase 3 study evaluating SB206 as a treatment for molluscum on track for targeted readout before the end of Q2 2023.
- Topline data on track for readout before the end of Q2 2023. Currently no FDA-approved therapies for the treatment of molluscum – Potential for NDA filing no later than Q3 2023
